Collaboration, License, and Other Agreements - Summary (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenues:
Revenue	$ 107,199	$ 108,637	$ 97,231	$ 97,529	$ 117,130	$ 103,747	$ 104,031	$ 88,845	$ 410,596	$ 413,753	$ 389,523
Collaborative arrangements revenue
Revenues:
Revenue									410,596	412,784	381,545
Collaborative arrangement, other agreements
Revenues:
Revenue									1,824	1,755	1,335
Sale of active pharmaceutical ingredient
Revenues:
Revenue										969	7,978
AbbVie Plc | Sale of active pharmaceutical ingredient
Revenues:
Revenue										223	421
AbbVie Plc | North America | Collaborative arrangements revenue
Revenues:
Revenue									401,498	403,085	370,902
AbbVie Plc | North America | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue									401,498	403,085	370,902
AbbVie Plc | Europe and Other | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue									2,444	2,558	2,196
AstraZeneca | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue									635	743	682
AstraZeneca | Sale of active pharmaceutical ingredient
Revenues:
Revenue										597	5,540
Astellas Pharma Inc. | Collaborative arrangement, collaboration and license agreements
Revenues:
Revenue									2,001	2,232	2,128
Astellas Pharma Inc. | Sale of active pharmaceutical ingredient
Revenues:
Revenue										149	2,017
Alnylam | Collaborative arrangement, co-promotion agreements
Revenues:
Revenue									$ 2,194	$ 2,411	$ 4,302